Cancer immunotherapy using Listeria monocytogenes and listerial virulence factors
- 177 Downloads
Our laboratory is interested in how immunogenicity may be modulated in vivo in order to better design more effective immunotherapeutics against cancer. Our main approach is to use a facultative intracellular bacterium, Listeria monocytogenes, which has the unusual ability to live and grow in the cytoplasm of the cell and is thus an excellent vector for targeting passenger antigens to the major histocompatibility complex (MHC) class I pathway of antigen processing with the generation of authentic CTL epitopes. We have used this approach to target tumor antigens expressed on breast, melanoma and cervical cancer. We are also exploring the role of Listerial virulence factors in potentiating adaptive immune responses by activating innate immunity. Specifically, we are using these proteins as adjuvants for B cell lymphomas.
KeywordsListeriamonocytogenes HPV Her-2/neu Tumor immunotherapy Tumor vasculature Vaccines Antigen processing Cell-mediated immunity
We thank all the current and past members of the Paterson laboratory for their contributions to these studies and, in particular Dr. Zhen-Kun Pan, for her unswerving support and industry for the past 18 years. Yvonne Paterson wishes to disclose that she has a financial interest in Advaxis, Inc., a vaccine and therapeutic company that has licensed or has an option to license all patents from the University of Pennsylvania that concern the use of Listeria or listerial products as vaccines.
- 1.Sabin A. Presidential Address to the Infectious Disease Society of America. 1983.Google Scholar
- 2.Paterson Y. Rational approaches to immune regulation. Immunol Res. 2003;27:451–62. (Cancro M, Monroe J, editors).Google Scholar
- 3.Paterson Y. The relationship between bacterial life-styles and the immune responsiveness to bacterially delivered antigens. In: Paterson Y, editor. Intracellular bacteria as live recombinant vaccine vectors Immunology cell biology and genetics. New York, NY: Wiley; 1999. p. 1–24.Google Scholar
- 11.Weiskirch L, Paterson Y. The use of Listeria monocytogenes recombinants as vaccine vectors in infectious and neoplastic disease. In: Paterson Y, editor. Chapter 7 in Intracellular bacteria as live recombinant vaccine vectors: Immunology, cell biology and genetics. New York, NY: Wiley; 1999. p. 223–59.Google Scholar
- 12.Vijh S, Pamer EG. The cell biology and immune response to Listeria monocytogenes, an intracellular pathogen. In: Paterson Y, editor. Chapter 3 in Intracellular bacteria as live recombinant vaccine vectors: Immunology, cell biology and genetics. New York, NY: Wiley; 1999.Google Scholar
- 26.Gunn GR, Zubair A, Peters CH, Pan Z-K, Wu T-C, Paterson Y. Two L. monocytogenes vaccine vectors that express different molecular forms of HPV-16 E7 induce qualitatively different T cell immunity that correlates with their ability to induce regression of established tumors immortalized by HPV-16. J Immunol. 2001;167:6471–9.PubMedGoogle Scholar
- 29.Lamikanra A, Pan Z-K, Isaacs S, Wu T-C, Paterson Y. The ability to induce the regression of established HPV-16 immortalized tumors in vivo by vaccinia viruses expressing different forms of HPV-16 E7 correlates with enhanced CD8+ T cell responses that home to the tumor site. J Virol. 2001;75:9654–64.PubMedCrossRefGoogle Scholar
- 43.Souders NC, Sewell DA, Pan Z-K, Hussain SF, Rodriguez A, Wallecha A, et al. Listeria based vaccines can overcome tolerance by expanding low avidity CD8+ T cells capable of eradicating a solid tumor in a transgenic mouse model of cancer. Cancer Immun. 2007;7:1–12.Google Scholar
- 52.Campoli MR, Chang CC, Kageshita T, Wang X, McCarthy JB, Ferrone S. Human high molecular weight-melanoma-associated antigen (HMW-MAA): a melanoma cell surface chondroitin sulfate proteoglycan (MSCP) with biological and clinical significance. Crit Rev Immunol. 2004;24:267–96.PubMedCrossRefGoogle Scholar